Marketing Authorisation Holders (MAH)
Table of Contents
Introduction
Marketing Authorisation Holders (MAH) are legal entities responsible for the approval, lifecycle management, and compliance of a pharmaceutical product within a given regulatory framework. As a critical regulatory designation, the MAH ensures that a drug or biological product meets safety, efficacy, and quality standards throughout its market lifespan.
Definitions and Concepts
Marketing Authorisation Holder (MAH): A company or organization that holds the license to market a pharmaceutical or biological product, granted by regulatory authorities such as the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA). The MAH is legally accountable for ensuring product compliance.
Marketing Authorisation (MA): An official approval required before a medicine can be marketed, ensuring it meets established standards of safety, efficacy, and quality.
Related terms include Post-Marketing Surveillance (monitoring safety after approval) and Variations (amendments made to an existing marketing authorisation).
Importance
The role of the Marketing Authorisation Holder is essential in maintaining the integrity and safety of pharmaceutical products. By ensuring compliance with stringent standards, MAHs enable:
- Consistent product availability across different markets.
- Timely reporting and management of adverse events during post-market use.
- Regulatory adherence in a landscape where non-compliance risks severe legal and financial consequences.
- Transparency and trust between manufacturers, healthcare providers, and patients.
For pharmaceutical companies, being an MAH represents not only regulatory responsibility but also a significant commercial and legal commitment related to market presence.
Principles or Methods
Key responsibilities and operational principles governing MAHs include:
- Regulatory Compliance: Ensuring all products under their authorization are manufactured, marketed, and distributed in line with the applicable laws and regulations.
- Pharmacovigilance: Establishing systems to monitor, collect, and report any adverse drug reactions as part of post-marketing surveillance.
- Lifecycle Management: Filing variations and renewals, updating safety profiles, and integrating regulatory updates for continued compliance with marketing authorisation.
- Communication with Authorities: Acting as the primary liaison with regulatory entities like the EMA, FDA, or WHO, especially during inspections, audits, or the market expansion process.
Application
In real-world scenarios, Marketing Authorisation Holders serve as the backbone of pharmaceutical and biotech companies seeking to bring their products to market globally. Some practical applications include:
- Filing marketing authorisation applications for new medicines, including dossier submission and clinical data evaluation for approval.
- Managing post-marketing obligations, such as Periodic Safety Update Reports (PSURs) and Risk Management Plans (RMPs).
- Overseeing global product registrations to ensure compliance across varying regulatory landscapes.
- Handling product recalls in cases of non-compliance or adverse events to protect patient safety while mitigating reputational risks.
Key examples include multinational companies acting as MAHs in multiple jurisdictions to streamline market access or partnerships with local distributors who assume MAH responsibilities in specific regions.
References
- European Medicines Agency (EMA) – Official guidelines and procedures for MAH responsibilities in the EU.
- U.S. Food and Drug Administration (FDA) – Overview of drug approval and MA responsibilities in the U.S.
- International Council for Harmonisation (ICH) – Guidelines for streamlined global regulatory processes, including MAHs.
- World Health Organization (WHO) – Standards and guidance on marketing authorisation in developing regions.
- Authoritative texts such as “Drug Safety Management” and articles in pharmaceutical journals like “Regulatory Affairs Professionals Society (RAPS)”.